NEW YORK (GenomeWeb News) – Olink Bioscience today announced a consortium formed to advance research into inflammatory bowel diseases.

The Inflammatory Bowel Disease Characterization by a multi-modal integrated biomarker study Consortium was launched in December with a €6 million ($7.7 million) grant from the European Commission's 7th Framework Program. The effort will run through Nov. 30, 2016.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.